 NEW YORK, Nov. 10, 2020 GLOBE NEWSWIRE -- Prevail Therapeutics Inc. Nasdaq: PRVL, a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the following virtual investor conferences in November and December: 